PURPOSE: Transrectal ultrasound guided prostate biopsy is widely used to confirm the diagnosis of prostate cancer. The technique has been associated with significant morbidity in a small proportion of patients. MATERIALS AND METHODS: We conducted a population based study of 75,190 men who underwent a transrectal ultrasound guided biopsy in Ontario, Canada, between 1996 and 2005. We used hospital and cancer registry administrative databases to estimate the rates of hospital admission and mortality due to urological complications associated with the procedure. RESULTS: Of the 75,190 men who underwent transrectal ultrasound biopsy 33,508 (44.6%) were diagnosed with prostate cancer and 41,682 (55.4%) did not have prostate cancer. The hospital admission rate for urological complications within 30 days of the procedure for men without cancer was 1.9% (781/41,482). The 30-day hospital admission rate increased from 1.0% in 1996 to 4.1% in 2005 (p for trend <0.0001). The majority of hospital admissions (72%) were for infection related reasons. The probability of being admitted to hospital within 30 days of having the procedure increased 4-fold between 1996 and 2005 (OR 3.7, 95% CI 2.0-7.0, p <0.0001). The overall 30-day mortality rate was 0.09% but did not change during the study period. CONCLUSIONS: The hospital admission rates for complications following transrectal ultrasound guided prostate biopsy have increased dramatically during the last 10 years primarily due to an increasing rate of infection related complications.
PURPOSE: Transrectal ultrasound guided prostate biopsy is widely used to confirm the diagnosis of prostate cancer. The technique has been associated with significant morbidity in a small proportion of patients. MATERIALS AND METHODS: We conducted a population based study of 75,190 men who underwent a transrectal ultrasound guided biopsy in Ontario, Canada, between 1996 and 2005. We used hospital and cancer registry administrative databases to estimate the rates of hospital admission and mortality due to urological complications associated with the procedure. RESULTS: Of the 75,190 men who underwent transrectal ultrasound biopsy 33,508 (44.6%) were diagnosed with prostate cancer and 41,682 (55.4%) did not have prostate cancer. The hospital admission rate for urological complications within 30 days of the procedure for men without cancer was 1.9% (781/41,482). The 30-day hospital admission rate increased from 1.0% in 1996 to 4.1% in 2005 (p for trend <0.0001). The majority of hospital admissions (72%) were for infection related reasons. The probability of being admitted to hospital within 30 days of having the procedure increased 4-fold between 1996 and 2005 (OR 3.7, 95% CI 2.0-7.0, p <0.0001). The overall 30-day mortality rate was 0.09% but did not change during the study period. CONCLUSIONS: The hospital admission rates for complications following transrectal ultrasound guided prostate biopsy have increased dramatically during the last 10 years primarily due to an increasing rate of infection related complications.
Authors: Stephen J Summers; Darshan P Patel; Blake D Hamilton; Angela P Presson; Mark A Fisher; William T Lowrance; Andrew W Southwick Journal: World J Urol Date: 2015-05-03 Impact factor: 4.226
Authors: Eugenio Martorana; Giacomo Maria Pirola; Maria Cristina Aisa; Pietro Scialpi; Aldo Di Blasi; Giovanni Saredi; Alfredo D'Andrea; Stefano Signore; Riccardo Grisanti; Michele Scialpi Journal: Turk J Urol Date: 2019-07-01
Authors: Ji Won Ryu; Seung Il Jung; Ji Hoon Ahn; Eu Chang Hwang; Ho Song Yu; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Jin Woong Kim Journal: Int Urol Nephrol Date: 2016-08-05 Impact factor: 2.370
Authors: Lana Pepdjonovic; Guan Hee Tan; Sean Huang; Sarah Mann; Mark Frydenberg; Daniel Moon; Uri Hanegbi; Adam Landau; Ross Snow; Jeremy Grummet Journal: World J Urol Date: 2016-12-16 Impact factor: 4.226
Authors: K Lahdensuo; A Rannikko; V-J Anttila; A Erickson; A Pätäri-Sampo; M Rautio; H Santti; E Tarkka; M Vaara; K Huotari Journal: Prostate Cancer Prostatic Dis Date: 2016-08-16 Impact factor: 5.554